MPP urges FDA to “phase down” amalgam use

MPP recently provided testimony to an FDA panel charged with re-examining  dental amalgam.  We pointed out  that while FDA panel re-evalutates, the World Health Organization  is expected to recommend that amalgam use be “phased down.”   “We welcome WHO’s  support for “phase down” , and urge FDA to do the same,” said MPP’s director.   The WHO is expected to soon final its meeting report in preparation for the upcoming  International Negotiations Committee deliberations  in Chiba, Japan, 24-28 January, 2011, that will ultimately lead to the adoption of a legally binding instrument on mercury by 2013.

WHO urged to correct misleading report on “Future of Dental Restorative Materials”

The European Environmental Bureau and MPP recently wrote a letter urging the World Health Organization (WHO) to correct inaccuracies, misleading and incorrect statements  before finalizing its meeting report.   Unfortunately, the draft report’s bias is already being diffused on various pro-amalgam websites, including one from Australia  and the other from the USA.  Among other things, the letter encourages WHO to correct for the record that the purpose of the meeting was to discuss alternatives to amalgam, and not debate or assert the safety of amalgam,  — and instead to highlight opportunities for “phasing down” the amalgam use, as WHO discussed in Stockholm in June.